# A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)

> **NCT00240929** · PHASE2 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 150 (actual)

## Conditions studied

- -Unhealthy Children With a History of Prematurity

## Interventions

- **DRUG:** MEDI-493

## Key facts

- **NCT ID:** NCT00240929
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** —
- **Final completion:** 2003-04
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2010-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00240929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00240929, "A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00240929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*